Immune Checkpoint Therapies in Prostate CancerGoswami, Sangeeta MD, PhD; Aparicio, Ana MD; Subudhi, Sumit K. MD, PhDThe Cancer Journal: March/April 2016 - Volume 22 - Issue 2 - p 117–120 doi: 10.1097/PPO.0000000000000176 Reviews Buy Abstract Author InformationAuthors Article MetricsMetrics Advanced prostate cancer is the second leading cause of death from cancer in the United States. In the era of cancer immunotherapy, it was the first malignancy to demonstrate improved survival with a cancer-specific vaccine, thus proving that prostate cancer is an immune-responsive disease. However, the success with immune checkpoint therapies in metastatic prostate cancer has been limited to date with only a subset of patients experiencing clinical benefit. The relative lack of response could be attributed to patient selection based on clinical attributes and the tumor microenvironment. Here, we review the current data on immune checkpoint therapies in prostate cancer and propose future directions. From the Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Sumit K. Subudhi, MD, PhD, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, 1155 Pressler St, Unit 1374, Houston, TX 77030. E-mail: email@example.com. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.